Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Hematopoiesis01:21

Hematopoiesis

5.1K
The process of blood cell formation is called hematopoiesis. Hematopoiesis starts early during development, on the seventh day of embryogenesis. This phase of hematopoiesis is called the primitive wave, wherein the extraembryonic yolk sac allows the production of erythroid cells and endothelial cells from a common precursor called hemangioblast. The erythroid cells provide oxygen to support the growth of the rapidly dividing embryo. Hemangioblasts later develop into hematopoietic stem cells or...
5.1K
Lineage Commitment01:21

Lineage Commitment

3.0K
Commitment is the  process whereby stem cells:
3.0K
Multipotency of Hematopoietic Stem Cells01:19

Multipotency of Hematopoietic Stem Cells

3.0K
The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
3.0K
Production of Formed Elements01:34

Production of Formed Elements

1.3K
Hemangioblasts are multipotent stem cells originating from the mesoderm. They give rise to hematopoietic stem cells (HSCs), which undergo hematopoiesis to produce all the formed elements of blood. This process is regulated by a complex network of hematopoietic growth factors, including transcription factors, growth factors, and cytokines. These factors stimulate the HSCs to divide and differentiate, though some HSCs remain undifferentiated to maintain a self-renewing pool.
Most HSCs commit to...
1.3K
Overview of Hematopoiesis01:20

Overview of Hematopoiesis

3.8K
Hematopoiesis, or blood cell production, is a vital biological process that begins early in embryonic development and continues throughout life. This process generates the various types of cells found in blood, including red blood cells, white blood cells, and platelets from hematopoietic stem cells (HSCs).
Developmental Phases of Hematopoiesis
Initially, HSCs are formed in the embryonic yolk sac, a critical site for early blood cell production. These stem cells subsequently migrate to other...
3.8K
Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

3.2K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.2K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Transferrin in combination with induction chemotherapy improves outcomes in mouse models of acute myeloid leukemia.

Science translational medicine·2026
Same author

Microglial clonal dynamics and the impact of clonal hematopoiesis in autologously transplanted rhesus macaques.

Cell reports·2026
Same author

Telomere length and clonal hematopoiesis interact to influence outcomes in hematopoietic stem cell transplantation.

Blood advances·2026
Same author

Inhibition of p300/CREBBP catalytic activity drives context-dependent transcriptional activation in AML.

Blood·2026
Same author

Polθ activity modulates sensitivity to standard therapies in DNMT3A-deficient leukemia.

Cell reports. Medicine·2026
Same author

The prevalence and clinical significance of clonal monocytosis.

Blood·2026

相关实验视频

Updated: Jun 11, 2025

Bone Marrow Transplantation Procedures in Mice to Study Clonal Hematopoiesis
08:00

Bone Marrow Transplantation Procedures in Mice to Study Clonal Hematopoiesis

Published on: May 26, 2021

12.4K

克隆性血液形成和血液性恶性瘤

William G Dunn1,2, Matthew A McLoughlin1, George S Vassiliou1,2

  • 1Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.

The Journal of clinical investigation
|October 1, 2024
PubMed
概括

由突变驱动的克隆性血液形成 (CH) 在老年人中很常见. 了解CH突变有助于预测和预防转变为髓状腺癌的进展.

科学领域:

  • 血液学 血液学 血液学
  • 遗传学 是一个遗传学.
  • 在瘤学瘤学.

背景情况:

  • 克隆造血 (CH) 涉及突变造血干细胞的扩张,随着年龄的增长而增加.
  • 冠状动脉炎通常是亚临床的,但可以发展为白血病等髓状瘤.
  • 最近的进展提高了对CH分子格局和相关风险的理解.

研究的目的:

  • 为了提供CH驱动器突变的概述.
  • 讨论CH的病理生理学.
  • 为了告知神经髓瘤恶性瘤风险估计在CH载体.

主要方法:

  • 关于克隆性血液形成的当前文献的综述.
  • 分析CH驱动突变的频谱.
  • 检查CH病理生理学与骨髓瘤瘤风险之间的联系.

主要成果:

  • 在70岁以上的人群中,CH是普遍存在的.
  • 在CH中发生的特定驱动基因突变会导致骨髓瘤形成的不同风险.
  • 现在可以对CH载体进行更好的风险分层.

结论:

更多相关视频

Characterizing Mutational Load and Clonal Composition of Human Blood
07:58

Characterizing Mutational Load and Clonal Composition of Human Blood

Published on: July 11, 2019

7.3K
Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

11.1K

相关实验视频

Last Updated: Jun 11, 2025

Bone Marrow Transplantation Procedures in Mice to Study Clonal Hematopoiesis
08:00

Bone Marrow Transplantation Procedures in Mice to Study Clonal Hematopoiesis

Published on: May 26, 2021

12.4K
Characterizing Mutational Load and Clonal Composition of Human Blood
07:58

Characterizing Mutational Load and Clonal Composition of Human Blood

Published on: July 11, 2019

7.3K
Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

11.1K
  • 了解CH的进展使得精确的骨髓瘤瘤风险评估成为可能.
  • 这些知识有助于制定策略来拦截CH的进展.
  • 有针对性的干预措施旨在防止CH演变为血液恶性瘤.